Stay updated on SL-401 Combo in AML/MDS/BPDCN Clinical Trial

Sign up to get notified when there's something new on the SL-401 Combo in AML/MDS/BPDCN Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the SL-401 Combo in AML/MDS/BPDCN Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the study details related to a Phase I clinical trial testing the safety and appropriate dosage of SL-401 in combination with azacitidine or azacitidine/venetoclax for the treatment of AML, BPDCN, and high-risk MDS.
    Difference
    0.1%
    Check dated 2024-06-06T14:34:03.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to 'Participation Criteria Researchers look for people who fit a certain description, called eligibility criteria.' This change provides a more detailed explanation of eligibility criteria, including examples such as a person's general health condition or prior treatments.
    Difference
    35%
    Check dated 2024-05-22T21:16:45.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    0.9%
    Check dated 2024-04-30T22:40:40.000Z thumbnail image

Stay in the know with updates to SL-401 Combo in AML/MDS/BPDCN Clinical Trial

Enter your email address, and we'll notify you when there's something new on the SL-401 Combo in AML/MDS/BPDCN Clinical Trial page.